抑制PRMT1通过通过FGF2/PI3K/Akt通路调节巨细胞来保护CoNV
Yuelan Gao1, Jiewen Mao1, Rui Zhang2
1Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
European journal of pharmacology
|May 30, 2024
概括
抑制蛋白质氨酸甲基转移酶1 (PRMT1) 通过通过FGF2/PI3K/Akt通路减少M2巨分化,减少角膜新血管化 (CoNV),为CoNV提供潜在的新疗法.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 角膜新血管化 (CoNV) 导致视力损伤,目前的治疗方法有限.
- 蛋白质氨酸甲基转移酶1 (PRMT1) 影响炎症和M2巨细胞两极分化,但其在CoNV中的作用尚不清楚.
研究的目的:
- 研究PRMT1在角膜新血管化 (CoNV) 中的机制,并评估PRMT1抑制作为治疗策略.
主要方法:
- 用于研究PRMT1抑制的性诱导的CONV的小鼠模型.
- 评估角膜损伤,新血管化,M2巨细胞两极分化和炎症因素.
- 研究了纤维细胞生长因子2 (FGF2) 和PI3K/Akt通路的作用.
- 使用人类静脉内皮细胞 (HUVEC) 和RAW264.7细胞进行确认.
主要成果:
- PRMT1水平与角膜损伤相关;抑制降低了不透明度和新血管化.
- 抑制PRMT1降低了FGF2表达和M2巨细胞极化.
- FGF2逆转了PRMT1抑制对M2极化的影响.
- 在CoNV.中,PRMT1通过FGF2/PI3K/Akt路径促进M2极化.
结论:
- 抑制PRMT1可以通过FGF2/PI3K/Akt路径抑制M2巨细胞极化来缓解角膜损伤和CoinV.
- 向PRMT1为角膜新血管化提供了一个有前途的治疗途径.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K


